Role of Remdesivir in COVID-19

Sumera Shaeen, N. Sattar, Mohammad A. A. Ibrahim, Muhammad Irfan
{"title":"Role of Remdesivir in COVID-19","authors":"Sumera Shaeen, N. Sattar, Mohammad A. A. Ibrahim, Muhammad Irfan","doi":"10.26420/AUSTINJPULMRESPIRMED.2021.1071","DOIUrl":null,"url":null,"abstract":"Remdesivir is an antiviral drug showed broad spectrum against viruses, also RNA polymerase inhibitor that’s why use to treat a variety of RNA virus infections. It is considered to be more effective against family of respiratory infection causing viruses including corona virus as compared to those whom it was originally synthesized like Hepatitis C and common cold viruses. On October 8, 2020, The National Institute of Allergy and Infectious Diseases has completed trials on COVID-19 patients and found Remdesivir satisfactory and beneficiary choice towards the recovery stairs of COVID-19. The pandemic of Covid-19 might wean down by season, but the possibility of reoccurrence exists. Thus, future clearance of Remdesivir might be critical for ensuring effective treatment, diminish mortality and permit early release.","PeriodicalId":90449,"journal":{"name":"Austin journal of pulmonary and respiratory medicine","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Austin journal of pulmonary and respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/AUSTINJPULMRESPIRMED.2021.1071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Remdesivir is an antiviral drug showed broad spectrum against viruses, also RNA polymerase inhibitor that’s why use to treat a variety of RNA virus infections. It is considered to be more effective against family of respiratory infection causing viruses including corona virus as compared to those whom it was originally synthesized like Hepatitis C and common cold viruses. On October 8, 2020, The National Institute of Allergy and Infectious Diseases has completed trials on COVID-19 patients and found Remdesivir satisfactory and beneficiary choice towards the recovery stairs of COVID-19. The pandemic of Covid-19 might wean down by season, but the possibility of reoccurrence exists. Thus, future clearance of Remdesivir might be critical for ensuring effective treatment, diminish mortality and permit early release.
瑞德西韦在COVID-19中的作用
雷姆德西韦是一种抗病毒药物,对病毒有广谱作用,也是RNA聚合酶抑制剂这就是为什么它被用来治疗各种RNA病毒感染。与丙型肝炎和普通感冒病毒等最初合成的病毒相比,它被认为对包括冠状病毒在内的呼吸道感染家族病毒更有效。2020年10月8日,美国国家过敏和传染病研究所完成了对COVID-19患者的试验,发现瑞德西韦令人满意,是COVID-19康复阶梯的受益者选择。新冠肺炎大流行可能会随着季节的变化而减弱,但再次发生的可能性仍然存在。因此,未来清除Remdesivir可能对确保有效治疗、降低死亡率和允许早期释放至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信